Nivolumab Designated Breakthrough Therapy for Hodgkin Lymphoma
The FDA has granted nivolumab (Bristol-Myers Squibb) Breakthrough Therapy designation for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant and brentuximab.